We discovered that the immunosuppressive tumor microenvironment was associated with a high prevalence of MAP3K1 mutation, suggesting that MAP3K1 plays an important role in mediating resistance to immunotherapy. This evidence concerns the gene MAP3K1 and neoplasm.